In-depth guides on cost, dosing, side effects, insurance coverage, and pharmacy pathways for tirzepatide.
Patient-focused guides covering the practical questions most people ask before, during, and after starting tirzepatide therapy. Each guide is built around how this question affects real treatment decisions: cost, insurance, dosing, side effects, and what compounded versus brand-name means. For deeper clinical reference, see the clinical reference section; for state-specific access information, see tirzepatide by state; for direct head-to-head comparisons, see side-by-side comparisons.
Most patients begin with a telehealth or in-person clinical visit to verify eligibility (BMI ≥30 or ≥27 with comorbidity for weight management; diabetes diagnosis for type 2 diabetes care). The provider reviews medical history, contraindications, and current medications, then writes a prescription. Insurance coverage is verified or a cash-pay pathway is chosen, and the medication is dispensed by a pharmacy.
Brand-name Zepbound list price is approximately $1,060 per month in 2026; Eli Lilly's self-pay vial program for select doses costs $349–$549 per month. Compounded tirzepatide from licensed pharmacies typically prices between $159 and $399 per month depending on dose and provider. Total annual cost without insurance can range from approximately $1,800 to $12,000+.
Weight loss typically begins within the first few weeks but is most pronounced over months. Mean weight loss continued through 72 weeks of treatment in the SURMOUNT-1 trial. Many patients see 5–10% body weight loss by month 3 and 15–20% by month 12 on adequate dosing.
Most clinicians recommend continuing tirzepatide as long-term therapy. The SURMOUNT-4 trial demonstrated substantial weight regain when patients were switched to placebo after initial weight loss. Tirzepatide is positioned analogously to medications for other chronic conditions — taken indefinitely under clinical supervision.